One aspect we did not explore was circulating levels of DKK1 and SOST in both naïve and myeloma‐bearing conditions, and the influence of either single or combination strategies with anti‐LRP6 and anti‐DKK1 on these antagonists. Here, LRP6 is linked to plasma cell myeloma.